Major peri-procedural complications |
Major
peri-procedural complications |
Major peri-procedural
complications |
Major peri-procedural complications |
Major peri-procedural complications |
Death, immediate peri-procedural (any), n (%) |
0 (0.0) |
0 (0.0) |
0
(0.0) |
>0.99 |
Need for cardio-pulmonary resuscitation, n (%) |
3 (0.6) |
3 (1.4) |
0
(0.0) |
0.07 |
Pericardial effusion requiring intervention, n (%) |
5 (1.0) |
2 (0.9) |
3 (1.0) |
>0.99 |
Stroke (any), n (%) |
2 (0.4) |
0 (0.0) |
2 (0.7) |
0.51 |
Major bleeding (≥BARC 3a), n (%) |
5 (1.0) |
2 (0.9) |
3 (1.0) |
>0.99 |
Need for bailout surgery, n (%) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
>0.99 |
Device embolization, n (%) |
2 (0.4) |
1 (0.5) |
1 (0.3) |
>0.99 |
Acute echocardiographic outcomes |
Acute
echocardiographic outcomes |
Acute echocardiographic outcomes |
Acute echocardiographic outcomes |
Acute
echocardiographic outcomes |
Residual flow, n (%) |
8 (1.5) |
3 (1.4) |
5 (1.6) |
>0.99 |
Significant flow, n (%) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
>0.99 |
DRT, n (%) |
1 (0.2) |
0 (0.0) |
1 (0.3) |
>0.99 |
Anti-thrombotic medical therapy post LAAC |
Anti-thrombotic medical therapy post LAAC |
Anti-thrombotic medical therapy post LAAC |
Anti-thrombotic medical therapy post LAAC |
Anti-thrombotic medical therapy post LAAC |
Any oral anticoagulation, n (%) |
270 (51.5) |
0 (0.0) |
34 (11.2) |
<0.01 |
Vitamin K antagonists, n (%) |
259 (49.4) |
0 (0.0) |
23 (7.6) |
<0.01 |
Non-vitamin K antagonists, n (%) |
11 (2.1) |
0 (0.0) |
11 (3.6) |
<0.01 |
Low molecular weight heparin, n (%) |
34 (6.5) |
0 (0.0) |
270 (88.8) |
<0.01 |
Aspirin, n (%) |
524 (100.0) |
220 (100.0) |
304 (100.0) |
>0.99 |
Platelet inhibitors other than aspirin, n (%) |
220 (42.0) |
220
(100.0) |
0 (0.0) |
<0.01 |